FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Bladder Cancer

In the phase 3 EV-302/KEYNOTE-A39 clinical trial, the antibody-drug conjugate enfortumab vedotin plus PD-1 inhibitor pembrolizumab nearly doubled both median overall survival and progression-free survival compared with chemotherapy.

Related Keywords

London ,City Of ,United Kingdom ,United States ,Americans ,Astellas Pharma ,Ahsan Arozullah ,Thomas Powles ,European Society For Medical Oncology Congress ,Barts Cancer Centre At St ,Olivier Le Moal ,European Society ,Medical Oncology Congress ,Barts Cancer Centre ,Enfortumab Vedotin ,Pembrolizumab ,Advanced Bladder Cancer ,Advanced Urothelial Carcinoma ,